Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The firm and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The firm has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). The company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. Its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
Follow-Up Questions
Polarean Imaging PLC (PLLWF)'in P/E oranı nedir?
Polarean Imaging PLC 'in P/E oranı N/A 'dir
Polarean Imaging PLC 'in CEO'su kimdir?
Dr. Christopher Von Jako 2023 'den beri şirketle birlikte olan Polarean Imaging PLC 'in Chief Executive Officer 'ıdır.
PLLWF hissesinin fiyat performansı nasıl?
PLLWF 'in mevcut fiyatı 0 'dir, son işlem günde 0% decreased etti.
Polarean Imaging PLC için ana iş temaları veya sektörler nelerdir?
Polarean Imaging PLC Health Care endüstrisine ait ve sektör Health Care 'dir
Polarean Imaging PLC 'in mevcut piyasa değerlemesi $0 'dir
Polarean Imaging PLC al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Polarean Imaging PLC için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 3 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
